1. The European Regional Agenda,
Science and Innovation
The HealthTIES answers
HealthTIES is an EU funded Regions of Knowledge for health program
we add

2. Content
 HealthTIES context
- Regional innovative ecosystems
- Health challenges in the 21st Century
 HealthTIES Regions of Knowledge project 2010 – 2013
- Approach
- Midterm results
- Outlook 2012-2013
we add

3. HealthTIES context
we add

4. Science-Innovation roadmaps
 Lisbon-Agenda
 Europe 2020; Flagship Initiative
 Innovation Union
 Europe Finance perspective 2014-2024
 European Research Management
From project approach to program and region approach
All focussing on creating a competitive European Research Area
we add

5. Common Strategic Framework
 Science for innovation (individual research group)
 Innovation for society (social demands)
 Innovation for competitiveness (industry)
 Focus, mass, social and economic impact
we add

6. EU innovation weaknesses
 Underinvestment in our knowledge foundation
 Unsatisfactory framework conditions
- access to finance
- high IPR costs
- slow standardisation
- ineffective use of public procurement
 To much fragmentation and costly duplication
Source: Europe 2020
we add

7. Contemporary healthcare
Challenges and Opportunities
 How do we improve medical care so as to live longer, healthier lives?
 How do we provide affordable medical care for the individual and the
society?
 Where do we find the trained people who will provide healthcare?
 How do we guarantee the quality and safety of our medical care?
 How can we use the “answers” to these questions to provide economic
opportunities?
we add

8. HealthTIES project
we add

9. HealthTIES regions are
Strong European regions in
 Life science &
 Medical technology
Both
 Scientific &
 Industrial
we add

10. The HealthTIES approach
Modeling Joint
Analysis
Fact Finding Action
SWOT
Virtual Reference Region Plan
Monitoring over years to come
we add

11. Modeling the ecosystem – WP2
Research funding Innovation system Companies
Spin off companies
Knowledge
Jobs
Business Development
Input output
R&D Infrastructure Patents
Products
Human Capital Facilities / Infrastructure Capital
we add

12. Data gathering of ecosystem – WP3
Approach
 Open sources for input and output
 “We all have pieces of the puzzle”
 Data needs to be reproducible
 Balance relevance vs accuracy
we add

13. Data gathering ecosystem – WP3
parameters
Input Innovation System Output
Profs H-factor >30 University spin-offs FTEs Biotech companies
Publications Granted US patents Biotech companies < and > 20 FTEs
Research funding WAIT indicator for countries Big trade sales
Internat./nat. grad. MSc students Big public-private projects Products on market
Internat./nat. PhD students TTO FTEs Products clinical trials
Junior/senior ERC grants Nat. govern. innov. support Products discovery phase
Research m2 Nat. attractiveness (WEF index) Medicines available in countries
Research hosptial beds Science parks m2 Total/number investments
Clinical trials phase I and II Science parks support FTEs Average Series A investments
we add

14. Benchmarking and best practices
Based upon
 key figures +
 Visits to each others
- scienceparks,
- universities,
- incubators etc.
we add

15. Virtual Reference Region
www.vrr.healthties.eu
we add

16. Strengths Weaknesses Opportunities Threats
Strengths Weaknesses
Excellent research Small, fragmented
environment bioscience parks
Good numbers of ERC Low numbers of research
grants and joint research students
projects Few research hospital beds
High investment levels and clinical trials
Good numbers of granted
US patents
Opportunities Threats
Improve innovation system Adverse economic
Capitalise on US patents environments
Increase start-ups and TTOs not maiximising their
attract more companies effectiveness for all
stakeholders
Improve job opportunities
Improve discovery and
availability of medicines
we add

17. Research and Development Strength - WP4
 Science via Web of Knowledge & Network
 Industry via Biotechgate.com & Network
we add

18. Outcomes WP4
Benchmark Web of Knowledge strengths 12 detailed research group collections
on matrix crossroads
we add

19. Analysis and best practices result in
regional and joint actions
HealthTIES – X Joint actions
EU regions in health innovation
Regional actions
Bench mark results
Region 1 Region 2 Region 3 Region 4 Region 5
we add

20. Actions following from analyses
Themes are
1. Innovation ecosystem
business development, incubator cooperation, investment fund,
clinical trial portal
2. Research, technology, development agenda
disseminate gained insights, increase joint RTD projects, smart
specialisation strategy, exchange of (teaching) staff etc.
3. Dissemination, increasing the participation of others
Keep involving our own regional stakeholders during JAP phase,
promote the VRR during conferences, actively invite other regions
to use it, keep improving the model
we add

21. Joint Action Plan WP5/6
Structure example
Barcelona Debrecen Medical Delta Oxford Zurich
Joint Action 1 participant participant participant participant Leader
Combining clinical trials
Joint Action 2 participant participant participant leader Participant
Joint R&D projects
Regional action 1 Already - Already Local Already
Setup incubator present present. leader present.
Advisor Advisor
Regional action 2 - Local leader Local leader advisor advisor
Increase ERC grants
Joint Action Plan is under construction.
Examples do not reflect the actual situation.
we add

22. JAP realization - format
Project: [Title] Project coordinator: [Name + organisation]
Description [Aim of the project + rationale (based upon analysis)]
Result in 2013
Others involved [names + organisations, from own region + from other HealthTIES regions if
applicable]
HealthTIES region [Region + name best practice]
with Best Practice
Approach [Describe the main and visible actions results in period 2012-2013, the budget
origin and involvement of experts etc.]
we add

23. Backup
we add

24. Industry in Medical Delta
current status in www.biotechgate.com
300 companies
18.000 industrial jobs
140 products on market
85 in development
we add

25. HealthTIES key People
Daily Board
Hans Goossens (Province of South Holland, coordinator)
Pancras Hogendoorn (LUMC, Scienctific director)
Roel Kamerling (Medical Delta / TU Delft, managing director
Laura Vis (Province of South Holland, Secretary Daily Board)
Executive Committee (= work package leaders + daily board)
Nerea Alonso (BioCat)
Bass Hassan and Laurel Edmunds (Oxford University)
Ernst Hafen and Silvia Gluderer (ETH Zurich)
Máté Rab and Brigitta Máté (Debrecen University)
In consortium board for Medical Delta
Henri Lenferink (Mayor of Leiden)
Huib Pols, dean of the Erasmus Medical Centre)
we add

26. Input results WP3
we add

27. Input results WP3
we add

28. Innovation system results WP3
we add

29. Innovation system results WP3
we add

30. Output results WP3
we add

31. Output results WP3
we add

32. Biocat
we add

33. Biocat
Strengths Weaknesses
High availability of Scarce phase 3/4 investm.
scientific profiles in life Lack of financial support at
sciences level of ideas
Good programmes Duplication of equipment
attracting foreign excellent
scientist Insufficient big PPPs
Important network of Weak valorisation
research hospi. performing structure in hospitals
clinical trials
High density of incubators
Opportunities Threats
Public procurement for Intensified debate on
innovations framework healthcare systems
European programmess sustainability
for boosting public-private Relocation of big pharma
partnerships R&D structures
Creation of new sectorial Difficulties to adapt to new
VC funds market paradigms
we add

34. Debrecen
we add

35. Debrecen
Strengths Weaknesses
Governmental innovation Little research, incubator and
support science park infrastructure
Many clinical trials in phase Few big PPPs
I and II Small qualified support staff
Attractive region for Few biotech companies
investors Few internat. renowned profs,
Many full-time employees few internat. students
Opportunities Threats
Public procurement for Intensified debate on
innovations framework healthcare systems
European programmess for sustainability
boosting public-private Relocation of big pharma
partnerships R&D structures
Creation of new sectorial Difficulties to adapt to new
VC funds market paradigms
we add

36. Medical Delta
we add

37. Medical Delta
we add

38. Oxford
we add

39. Oxford
we add

40. Zurich
we add

41. Zurich
we add

42. Input
Innovation system
Output
Products
we add

43. Worldwide context
we add